Japan Mulls Longer Drug Patents

Law360, New York (May 17, 2005, 12:00 AM EDT) -- Japan is considering an extension of drug parents from the current six years to eight years, according to a published report.

Japan's Ministry of Health, Labour and Welfare is considering whether to extend the the country's patent protection period for new drug products in order to provide manufacturers with better research incentives and profits, the Nihon Keizai Shimbun reported.

Sales of generic versions are banned for six years in Japan, during which new drugs enjoy high government-set prices.

Comparable protection in major European countries covers about...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.